One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Iradimed Corp before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Iradimed Corp’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Iradimed Corp’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Iradimed Corp (IRMD)

Before we jump into Iradimed Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient?s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gausses.

Want to learn more about Iradimed Corp’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Iradimed Corp. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Iradimed Corp’s Stock Price as of Market Close

As of April 06, 2023, 4:00 PM CST, Iradimed Corp’s stock price was $40.92.

Iradimed Corp is up 4.82% from its previous closing price of $39.04.

During the last market session, Iradimed Corp’s stock traded between $38.30 and $39.19. Currently, there are 12.57 million shares of Iradimed Corp stock available for purchase.

Iradimed Corp’s price-earnings (P/E) ratio is currently at 38.5, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 34.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Iradimed Corp Stock Price History

Iradimed Corp’s (IRMD) price is currently up 3.99% so far this month.

During the month of April, Iradimed Corp’s stock price has reached a high of $41.00 and a low of $36.83.

Over the last year, Iradimed Corp has hit prices as high as $45.80 and as low as $26.00. Year to date, Iradimed Corp’s stock is down 11.45%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Iradimed Corp Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 05, 2023, there were 0 analysts who downgraded Iradimed Corp’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Iradimed Corp’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Iradimed Corp’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Iradimed Corp (IRMD) by visiting AAII Stock Evaluator.

Relative Price Strength of Iradimed Corp

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of April 05, 2023, Iradimed Corp has a weighted four-quarter relative price strength of 5.09%, which translates to a Momentum Score of 80 and is considered to be Strong.

Want to learn more about how Iradimed Corp is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Iradimed Corp Stock Price: Bottom Line

As of April 6, 2023, Iradimed Corp’s stock price is $40.92, which is up 4.82% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Iradimed Corp’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.